1167 Stock Overview
An investment holding company, engages in the in-house discovery and development of oncology therapies.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Jacobio Pharmaceuticals Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.06 |
| 52 Week High | HK$9.89 |
| 52 Week Low | HK$1.81 |
| Beta | 0.68 |
| 11 Month Change | -18.25% |
| 3 Month Change | -39.41% |
| 1 Year Change | -76.19% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -87.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1167 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -16.3% | -0.6% | -0.8% |
| 1Y | -76.2% | -34.9% | -1.1% |
Return vs Industry: 1167 underperformed the Hong Kong Biotechs industry which returned -42.3% over the past year.
Return vs Market: 1167 underperformed the Hong Kong Market which returned -15.9% over the past year.
Price Volatility
| 1167 volatility | |
|---|---|
| 1167 Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in HK Market | 14.9% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 1167's share price has been volatile over the past 3 months.
Volatility Over Time: 1167's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 300 | Yinxiang Wang | www.jacobiopharma.com |
Jacobio Pharmaceuticals Group Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company’s lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It also develops JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-(L)1 resistant cancer; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations.
Jacobio Pharmaceuticals Group Co., Ltd. Fundamentals Summary
| 1167 fundamental statistics | |
|---|---|
| Market cap | HK$1.63b |
| Earnings (TTM) | -HK$445.97m |
| Revenue (TTM) | HK$88.47m |
14.7x
P/S Ratio-2.9x
P/E RatioIs 1167 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1167 income statement (TTM) | |
|---|---|
| Revenue | CN¥81.39m |
| Cost of Revenue | CN¥75.19m |
| Gross Profit | CN¥6.20m |
| Other Expenses | CN¥416.52m |
| Earnings | -CN¥410.32m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | 7.62% |
| Net Profit Margin | -504.11% |
| Debt/Equity Ratio | 4.8% |
How did 1167 perform over the long term?
See historical performance and comparison